Drug-eluting implants for osteomyelitis

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 24, Issue 6, 2007, Pages 493-545

  Soundrapandian, Chidambaram ^a   Datta, Someswar ^b   Sa, Biswanath ^a  

^a JADAVPUR UNIVERSITY   (India)

^b CSIR CENTRAL GLASS AND CERAMIC RESEARCH INSTITUTE   (India)

Author keywords

Bone; Drug delivery systems; Infection; Local delivery

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPICILLIN; BIOCERAMICS; BIOPOLYMER; CEFALEXIN; CEFAZOLIN; CEFMETAZOLE; CEFTAZIDIME; CEFUROXIME; CLINDAMYCIN; DAPTOMYCIN; DIBEKACIN; DRUG CARRIER; FLOMOXEF; FLUCONAZOLE; FOSFOMYCIN; FUSIDATE SODIUM; GATIFLOXACIN; GENTAMICIN; HABEKACIN; ISEPAMICIN; LACTOFERRIN; MEROPENEM; MINOCYCLINE; OFLOXACIN; PEFLOXACIN; POLYMYXIN B; UNINDEXED DRUG; VANCOMYCIN;

ANTIMICROBIAL THERAPY; BIOFILM; BIOMECHANICS; BLOOD FLOW; BONE EROSION; BONE GROWTH; COMPOSITE MATERIAL; COMPRESSION; DRUG DELIVERY SYSTEM; DRUG ELUTING IMPLANT; DRUG RELEASE; EMULSION; IMPLANT; MATERIAL COATING; OSTEOMYELITIS; PATHOGENESIS; POROSITY; PREVALENCE; REVIEW;

EID: 39049114654     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v24.i6.10     Document Type: Review

References (245)

1. Henry SL, Seligson D, Mangino P, Popham GJ. Antibiotic-impregnated beads. Part I: bead implantation versus systemic therapy. Orthop Rev. 1991;20:242-7.
2. Li LC, Deng J, Stephens D. Polyanhydride implant for antibiotic delivery - from the bench to the clinic. Adv Drug Deliv Rev. 2002;54:963-86.
3. Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs. 2000;59:1223-32.
4. Garvin K, Feschuk C. Polylactide-polyglycolide antibiotic implants. Clin Orthop Relat Res. 2005;437:105-10.
5. Bone online. Encyclopaedia Britannica Online; 2007. http://www. britannica.com/ebc/art-66017.
6. Wehrli FW, Fernandez-Seara MA. Nuclear magnetic resonance studies of bone water. Ann Biomed Eng. 2005;33:79-86.
7. Bone. Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow. Available from: http://www.gla.ac.uk/ibls/fab/tutorial/generic/bone1. html.
8. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364:369-79.
9. Carek PJ, Dickerson LM, Sack JL. Diagnosis and management of osteomyelitis. Am Fam Physician. 2001;63:2413-20.
10. Bisland SK, Chien C, Wilson BC, Burch S. Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. Photochem Photobiol Sci. 2006;5:31-8.
11. Muller E, Takeda S, Goldmann DA, Pier GB. Blood proteins do not promote adherence of coagulase-negative staphylococci to biomaterials. Infect Immun. 1991;59:3323-6.
12. Dougherty SH, Simmons RL. Infections in bionic man: the pathobiology of infections in prosthetic devices - Part I. Curr Probl Surg. 1982;19:217-64.
13. Dougherty SH, Simmons RL. Infections in bionic man: the pathobiology of infections in prosthetic devices - Part II. Curr Probl Surg. 1982;19:265-319.
14. Rittmann WW, Schibli M, Matter P, Allgower M. Open fractures. Long-term results in 200 consecutive cases. Clin Orthop Relat Res. 1979;138:132-40.
15. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am. 1976;58:453-8.
16. Hendriks JG, van Horn JR, van der Mei HC, Busscher HJ. Backgrounds of antibiotic-loaded bone cement and prosthesis-related infection. Biomaterials. 2004;25:545-56.
17. Harris WH, Sledge CB. Total hip and total knee replacement (2). N Engl J Med. 1990;323:801-7.
18. Chung R, Bivins BA. Antimicrobial prophylaxis in surgery. A synopsis. Infectious Diseases Newsletter. 1991;10:1-4.
19. Warnawin E, Burakowski T, Gajewski M, Radzikowska A, Kornatka A, Michalak C, Maldyk P, Maoelinski S, Maoelinski W. Preservation of chondrogenic potential of mesenchymal stem cells isolated from osteoarthritic patients during proliferation in response to platelet-derived growth factor (PDGF). Centr Eur J Immunol. 2005;30:26-31.
20. Bone. Department of Orthopaedic Surgery, University of Aberdeen; 2007. Available from: http://www.abdn.ac.uk/orthopaedics/res_bone.shtml.
21. Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis. 2001;33:1567-72.
22. Sculco TP. The economic impact of infected total joint arthroplasty. Instr Course Lect. 1993;42:349-51.
23. Benson MK, Hughes SP. Infection following total hip replacement in a general hospital without special orthopaedic facilities. Acta Orthop Scand. 1975;46:968-78.
24. Grogan TJ, Dorey F, Rollins J, Amstutz HC. Deep sepsis following total knee arthroplasty. Ten-year experience at the University of California at Los Angeles Medical Center. J Bone Joint Surg Am. 1986;68:226-34.
25. Salvati EA, Robinson RP, Zeno SM, Koslin BL, Brause BD, Wilson PD Jr. Infection rates after 3175 total hip and total knee replacements performed with and without a horizontal unidirectional filtered air-flow system. J Bone Joint Surg Am. 1982;64:525-35.
26. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:382-7.
27. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg. 1998;176:5S-10S.
28. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot. Soft tissue and bone infection. Infect Dis Clin North Am. 1990;4:409-32.
29. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29:1288-93.
30. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790-5.
31. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis. 1997;25:1318-26.
32. Norden CW. Lessons learned from animal models of osteomyelitis. Rev Infect Dis. 1988;10:103-10.
33. Belmatoug N, Cremieux AC, Bleton R, Volk A, Saleh-Mghir A, Grossin M, Garry L, Carbon C. A new model of experimental prosthetic joint infection due to methicillin-resistant Staphylococcus aureus: a microbiologic, histopathologic, and magnetic resonance imaging characterization. J Infect Dis. 1996;174:414-7.
34. Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest. 1984;73:1191-200.
35. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med. 1997;336:999-1007.
36. Mackowiak PA, Jones SR, Smith JW. Diagnostic value of sinus-tract cultures in chronic osteomyelitis. JAMA. 1978;239:2772-5.
37. Perry CR, Pearson RL, Miller GA. Accuracy of cultures of material from swabbing of the superficial aspect of the wound and needle biopsy in the preoperative assessment of osteomyelitis. J Bone Joint Surg Am. 1991;73:745-9.
38. Haas DW, McAndrew MP. Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. Am J Med. 1996;101:550-61.
39. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob. 2006;5:2.
40. Dirschl DR, Almekinders LC. Osteomyelitis. Common causes and treatment recommendations. Drugs. 1993;45:29-43.
41. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis. 1999;5:9-17.
42. Wheat LJ, Allen SD, Henry M, Kernek CB, Siders JA, Kuebler T, Fineberg N, Norton J. Diabetic foot infections. Bacteriologic analysis. Arch Intern Med. 1986;146:1935-40.
43. Quie PG, Belani KK. Coagulase-negative staphylococcal adherence and persistence. J Infect Dis. 1987;156:543-7.
44. Mahan J, Seligson D, Henry SL, Hynes P, Dobbins J. Factors in pin tract infections. Orthopedics. 1991;14:305-8.
45. Kaplan SS, Heine RP, Simmons RL. Defensins impair phagocytic killing by neutrophils in biomaterial-related infection. Infect Immun. 1999;67:1640-5.
46. Gristina AG. Implant failure and the immuno-incompetent fibro-inflammatory zone. Clin Orthop Relat Res. 1994;298:106-18.
47. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad Med J. 2000;76:479-83.
48. Campoccia D, Montanaro L, Arciola CR. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomaterials. 2006;27:2331-9.
49. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis. 1982;146:487-97.
50. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B. Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun. 1996;64:2371-80.
51. Waldvogel FA, Papageorgiou PS. Osteomyelitis: the past decade. N Engl J Med. 1980;303:360-70.
52. Vuong C, Gerke C, Somerville GA, Fischer ER, Otto M. Quorum-sensing control of biofilm factors in Staphylococcus epidermidis. J Infect Dis. 2003;188:706-18.
53. Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, Dasgupta M, Marrie TJ. Bacterial biofilms in nature and disease. Annu Rev Microbiol. 1987;41:435-64.
54. de Beer D, Stoodley P, Lewandowski Z. Measurement of local diffusion coefficients in biofilms by microinjection and confocal microscopy. Biotechnol Bioeng. 1997;53:151-8.
55. Stewart PS, Roe F, Rayner J, Elkins JG, Lewandowski Z, Ochsner UA, Hassett DJ. Effect of catalase on hydrogen peroxide penetration into Pseudomonas aeruginosa biofilms. Appl Environ Microbiol. 2000;66:836-8.
56. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 2005;13:34-40.
57. Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother. 1990;34:2043-6.
58. Carmen JC, Roeder BL, Nelson JL, Beckstead BL, Runyan CM, Schaalje GB, Robison RA, Pitt WG. Ultrasonically enhanced vancomycin activity against Staphylococcus epidermidis biofilms in vivo. J Biomater Appl. 2004;18:237-45.
59. Rediske AM, Roeder BL, Nelson JL, Robison RL, Schaalje GB, Robison RA, Pitt WG. Pulsed ultrasound enhances the killing of Escherichia coli biofilms by aminoglycoside antibiotics in vivo. Antimicrob Agents Chemother. 2000;44:771-2.
60. Qian Z, Sagers RD, Pitt WG. Investigation of the mechanism of the bioacoustic effect. J Biomed Mater Res A. 1999;44:198-205.
61. Ensing GT, Roeder BL, Nelson JL, van Horn JR, van der Mei HC, Busscher HJ, Pitt WG. Effect of pulsed ultrasound in combination with gentamicin on bacterial viability in biofilms on bone cements in vivo. J Appl Microbiol. 2005;99:443-8.
62. Pickering SA, Bayston R, Scammell BE. Electromagnetic augmentation of antibiotic efficacy in infection of orthopaedic implants. J Bone Joint Surg Br. 2003;85:588-93.
63. Benson DE, Grissom CB, Burns GL, Mohammad SF. Magnetic field enhancement of antibiotic activity in biofilm forming Pseudomonas aeruginosa. ASAIO J. 1994;40:M371-6.
64. Hughes SP, Anderson FM. Penetration of antibiotics into bone. J Antimicrob Chemother. 1985;15:517-9.
65. Tothill P, Hooper G, McCarthy ID, Hughes SP. The variation with flow-rate of the extraction of bone-seeking tracers in recirculation experiments. Calcif Tissue Int. 1985;37:312-7.
66. McCarthy ID, Hughes SP. The role of skeletal blood flow in determining the uptake of 99mtc-methylene diphosphonate. Calcif Tissue Int. 1983;35:508-11.
67. Mader J, Adams K. Experimental osteomyelitis. In: Schlossberg D, editor. Orthopedic infection. New York: Springer-Verlag; 1988. p. 39-48.
68. Mader JT, Adams K, Morrison L. Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother. 1989;33:1760-4.
69. Morris MA, Lopez-Curto JA, Hughes SP, An KN, Bassingthwaighte JB, Kelly PJ. Fluid spaces in canine bone and marrow. Microvasc Res. 1982;23:188-200.
70. Cierny G III, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003;414:7-24.
71. Simpson AH, Deakin M, Latham JM. Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival. J Bone Joint Surg Br. 2001;83:403-7.
72. Shuford JA, Steckelberg JM. Role of oral antimicrobial therapy in the management of osteomyelitis. Curr Opin Infect Dis. 2003;16:515-9.
73. Mader JT, Calhoun J. Osteomyelitis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2000. p. 1182-96.
74. Shinto Y, Uchida A, Korkusuz F, Araki N, Ono K. Calcium hydroxyapatite ceramic used as a delivery system for antibiotics. J Bone Joint Surg Br. 1992;74:600-4.
75. Desevaux C, Lenaerts V, Girard C, Dubreuil P. Characterization of crosslinked high amylose starch matrix implants. 2. In vivo release of ciprofloxacin. J Control Release. 2002;82:95-103.
76. Lazarettos J, Efstathopoulos N, Papagelopoulos PJ, Savvidou OD, Kanellakopoulou K, Giamarellou H, Giamarellos-Bourboulis EJ, Nikolaou V, Kapranou A, Papalois A, Papachristou G. A bioresorbable calcium phosphate delivery system with teicoplanin for treating MRSA osteomyelitis. Clin Orthop Relat Res. 2004;423:253-8.
77. Turner TM, Urban RM, Hall DJ, Chye PC, Segreti J, Gitelis S. Local and systemic levels of tobramycin delivered from calcium sulfate bone graft substitute pellets. Clin Orthop Relat Res. 2005;437:97-104.
78. Changez M, Koul V, Dinda AK. Efficacy of antibiotics-loaded interpenetrating network (IPNS) hydrogel based on poly(acrylic acid) and gelatin for treatment of experimental osteomyelitis: in vivo study. Biomaterials. 2005;26:2095-104.
79. Habib M, Onyilofor S, Ebube NK, Owusu-Ababio G. Preparation and characterization of ofloxacin microspheres for the eradication of bone associated bacterial biofilm. J Microencapsul. 1999;16:27-37.
80. Jiranek WA, Hanssen AD, Greenwald AS. Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. J Bone Joint Surg Am. 2006;88:2487-500.
81. Hanssen AD. Prophylactic use of antibiotic bone cement: an emerging standard - in opposition. J Arthroplasty. 2004;19:73-7.
82. Buchholz HW, Elson RA, Engelbrecht E, Lodenkamper H, Rottger J, Siegel A. Management of deep infection of total hip replacement. J Bone Joint Surg Br. 1981;63:342-53.
83. Picknell B, Mizen L, Sutherland R. Antibacterial activity of antibiotics in acrylic bone cement. J Bone Joint Surg Br. 1977;59:302-7.
84. Nijhof MW, Fleer A, Hardus K, Vogely HC, Schouls LM, Verbout AJ, Dhert WJ. Tobramycin-containing bone cement and systemic cefazolin in a one-stage revision. Treatment of infection in a rabbit model. J Biomed Mater Res B: Appl Biomater. 2001;58B:747-53.
85. Rushton N. Applications of local antibiotic therapy. Eur J Surg Suppl. 1997;578:27-30.
86. Perry AC, Rouse MS, Khaliq Y, Piper KE, Hanssen AD, Osmon DR, Steckelberg JM, Patel R. Antimicrobial release kinetics from polymethylmethacrylate in a novel continuous flow chamber. Clin Orthop Relat Res. 2002;403:49-53.
87. Marra F, Robbins GM, Masri BA, Duncan C, Wasan KM, Kwong EH, Jewesson PJ. Amphotericin B-loaded bone cement to treat osteomyelitis caused by Candida albicans. Can J Surg. 2001;44:383-6.
88. Queiroz AC, Santos JD, Monteiro FJ, Gibson IR, Knowles JC. Adsorption and release studies of sodium ampicillin from hydroxyapatite and glass-reinforced hydroxyapatite composites. Biomaterials. 2001;22:1393-400.
89. Itokazu M, Ohno T, Tanemori T, Wada E, Kato N, Watanabe K. Antibiotic-loaded hydroxyapatite blocks in the treatment of experimental osteomyelitis in rats. J Med Microbiol. 1997;46:779-83.
90. Mendel V, Simanowski HJ, Scholz HC, Heymann H. Therapy with gentamicin-PMMA beads, gentamicin-collagen sponge, and cefazolin for experimental osteomyelitis due to Staphylococcus aureus in rats. Arch Orthop Trauma Surg. 2005;125:363-8.
91. Kawanabe K, Okada Y, Matsusue Y, Iida H, Nakamura T. Treatment of osteomyelitis with antibiotic-soaked porous glass ceramic. J Bone Joint Surg Br. 1998;80:527-30.
92. Utsui Y, Ohya S, Magaribuchi T, Tajima M, Yokota T. Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1986;30:917-22.
93. Ng WM, Kwan MK, Merican AM. Melioidotic osteomyelitis treated with antibiotic-calcium hydroxyapatite composite: case report with four-year follow-up. Singapore Med J. 2006;47:71-4.
94. Schofield SC, Berno B, Langman M, Hall G, Filiaggi MJ. Gelled calcium polyphosphate matrices delay antibiotic release. J Dent Res. 2006;85:643-7.
95. Mader JT, Calhoun J, Cobos J. In vitro evaluation of antibiotic diffusion from antibiotic-impregnated biodegradable beads and polymethylmethacrylate beads. Antimicrob Agents Chemother. 1997;41:415-8.
96. Otsuka M, Sawada M, Matsuda Y, Nakamura T, Kokubo T. Antibiotic delivery system using bioactive bone cement consisting of Bis-GMA/TEGDMA resin and bioactive glass ceramics. Biomaterials. 1997;18:1559-64.
97. Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Patel R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother. 2006;57:301-5.
98. Faber C, Stallmann HP, Lyaruu DM, de Blieck JM, Bervoets TJ, van Nieuw Amerongen A, Wuisman PI. Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads. J Antimicrob Chemother. 2003;51:1359-64.
99. Wei G, Kotoura Y, Oka M, Yamamuro T, Wada R, Hyon SH, Ikada Y. A bioabsorbable delivery system for antibiotic treatment of osteomyelitis. The use of lactic acid oligomer as a carrier. J Bone Joint Surg Br. 1991;73:246-52.
100. Hasegawa M, Sudo A, Komlev VS, Barinov SM, Uchida A. High release of antibiotic from a novel hydroxyapatite with bimodal pore size distribution. J Biomed Mater Res B: Appl Biomater. 2004;70B:332-9.
101. Soriano I, Martin AY, Evora C, Sanchez E. Biodegradable implantable fluconazole delivery rods designed for the treatment of fungal osteomyelitis: influence of gamma sterilization. J Biomed Mater Res A. 2006;77:632-8.
102. El-Kamel AH, Baddour MM. Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation. Drug Deliv. 2007;14:349-56.
103. Virto MR, Elorza B, Torrado S, Elorza Mde L, Frutos G. Improvement of gentamicin poly(D,L-lactic-co-glycolic acid) microspheres for treatment of osteomyelitis induced by orthopedic procedures. Biomaterials. 2007;28:877-85.
104. Stallmann HP, Faber C, Bronckers AL, Nieuw Amerongen AV, Wuisman PI. Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement. J Antimicrob Chemother. 2004;54:472-6.
105. Persson C, Baleani M, Guandalini L, Tigani D, Viceconti M. Mechanical effects of the use of vancomycin and meropenem in acrylic bone cement. Acta Orthop. 2006;77:617-21.
106. Darouiche RO, Mansouri MD, Zakarevicz D, Alsharif A, Landon GC. In vivo efficacy of antimicrobial-coated devices. J Bone Joint Surg Am. 2007;89:792-7.
107. Chen L, Wang H, Wang J, Chen M, Shang L. Ofloxacin-delivery system of a polyanhydride and polylactide blend used in the treatment of bone infection. J Biomed Mater Res B: Appl Biomater. 2007;83B:589-95.
108. Andreopoulos AG, Hatzi EC, Doxastakis M. Controlled release systems based on poly(lactic acid). An in vitro and in vivo study. J Mater Sci Mater Med. 2000;11:393-7.
109. Kimakhe S, Bohic S, Larrose C, Reynaud A, Pilet P, Giumelli B, Heymann D, Daculsi G. Biological activities of sustained polymyxin B release from calcium phosphate biomaterial prepared by dynamic compaction: an in vitro study. J Biomed Mater Res A. 1999;47:18-27.
110. Cevher E, Orhan Z, Sensoy D, Ahiskali R, Kan PL, Sagirli O, Mulazimoglu L. Sodium fusidate-poly(D,L-lactide-co-glycolide) microspheres: preparation, characterisation and in vivo evaluation of their effectiveness in the treatment of chronic osteomyelitis. J Microencapsul. 2007;24:577-95.
111. Turesin F, Gursel I, Hasirci V. Biodegradable polyhydroxyalkanoate implants for osteomyelitis therapy: in vitro antibiotic release. J Biomater Sci Polym Ed. 2001;12:195-207.
112. Gurselt I, Yagmurlu F, Korkusuz F, Hasirci V. In vitro antibiotic release from poly(3-hydroxybutyrate-co-3-hydroxyvalerate) rods. J Microencapsul. 2002;19:153-64.
113. Tuzuner T, Sencan I, Ozdemir D, Alper M, Duman S, Yavuz T, Yildirim M. In vivo evaluation of teicoplanin- and calcium sulfate-loaded PMMA bone cement in preventing implant-related osteomyelitis in rats. J Chemother. 2006;18:628-33.
114. Kim HW, Knowles JC, Kim HE. Effect of biphasic calcium phosphates on drug release and biological and mechanical properties of poly(epsilon-caprolactone) composite membranes. J Biomed Mater Res A. 2004;70:467-79.
115. Papagelopoulos PJ, Mavrogenis AF, Tsiodras S, Vlastou C, Giamarellou H, Soucacos PN. Calcium sulphate delivery system with tobramycin for the treatment of chronic calcaneal osteomyelitis. J Int Med Res. 2006;34:704-12.
116. Niikura T, Tsujimoto K, Yoshiya S, Tadokoro K, Kurosaka M, Shiba R. Vancomycin-impregnated calcium phosphate cement for methicillin-resistant Staphylococcus aureus femoral osteomyelitis. Orthopedics. 2007;30:320-1.
117. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother. 2004;53:928-35.
118. Norden CW, Shaffer M. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. J Infect Dis. 1983;147:352-7.
119. Verklin RM Jr, Mandell GL. Alteration of effectiveness of antibiotics by anaerobiosis. J Lab Clin Med. 1977;89:65-71.
120. Tack KJ, Sabath LD. Increased minimum inhibitory concentrations with anaerobiasis for tobramycin, gentamicin, and amikacin, compared to latamoxef, piperacillin, chloramphenicol, and clindamycin. Chemotherapy. 1985;31:204-10.
121. Stallmann HP, Faber C, Nieuw Amerongen AV, Wuisman PI. Antimicrobial peptides: review of their application in musculoskeletal infections. Injury. 2006;37:S34-40.
122. Holtom PD, Pavkovic SA, Bravos PD, Patzakis MJ, Shepherd LE, Frenkel B. Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro. J Orthop Res. 2000;18:721-7.
123. Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res. 1998;16:509-12.
124. Isefuku S, Joyner CJ, Simpson AH. Toxic effect of rifampicin on human osteoblast-like cells. J Orthop Res. 2001;19:950-4.
125. Isefuku S, Joyner CJ, Simpson AH. Gentamicin may have an adverse effect on osteogenesis. J Orthop Trauma. 2003;17:212-6.
126. Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE. Bone toxicity of locally applied aminoglycosides. J Orthop Trauma. 1995;9:401-6.
127. Edin ML, Miclau T, Lester GE, Lindsey RW, Dahners LE. Effect of cefazolin and vancomycin on osteoblasts in vitro. Clin Orthop Relat Res. 1996;333:245-51.
128. Wong MWN, Hui M. Development of gentamicin resistance after gentamicin-PMMA beads for treatment of foot osteomyelitis: report of two cases. Foot Ankle Int. 2005;26:1093-5.
129. Ambrose CG, Clyburn TA, Louden K, Joseph J, Wright J, Gulati P, Gogola GR, Mikos AG. Effective treatment of osteomyelitis with biodegradable microspheres in a rabbit model. Clin Orthop Relat Res. 2004;421:293-9.
130. Naraharisetti PK, Guan Lee HC, Fu YC, Lee DJ, Wang CH. In vitro and in vivo release of gentamicin from biodegradable discs. J Biomed Mater Res B: Appl Biomater. 2006;77B:329-37.
131. Yenice I, Calis S, Atilla B, Kas HS, Ozalp M, Ekizoglu M, Bilgili H, Hincal AA. In vitro/in vivo evaluation of the efficiency of teicoplanin-loaded biodegradable microparticles formulated for implantation to infected bone defects. J Microencapsul. 2003;20:705-17.
132. Niemela SM, Ikaheimo I, Koskela M, Veiranto M, Suokas E, Tormala P, Waris T, Ashammakhi N, Syrjala H. Ciprofloxacin-releasing bioabsorbable polymer is superior to titanium in preventing Staphylococcus epidermidis attachment and biofilm formation in vitro. J Biomed Mater Res B: Appl Biomater. 2006;76B:8-14.
133. Du J, Jasti B, Vasavada RC. Controlled release of tobramycin sulfate from poly(ortho esters) implantable discs for the treatment of osteomyelitis. J Control Release. 1997;43:223-33.
134. Dash AK, Suryanarayanan R. An implantable dosage form for the treatment of bone infections. Pharm Res. 1992;9:993-1002.
135. Gursel I, Korkusuz F, Turesin F, Alaeddinoglu NG, Hasirci V. In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Biomaterials. 2001;22:73-80.
136. Korkusuz F, Korkusuz P, Eksioglu F, Gursel I, Hasirci V. In vivo response to biodegradable controlled antibiotic release systems. J Biomed Mater Res A. 2001;55:217-28.
137. Deng JS, Meisters M, Li L, Setesak J, Claycomb L, Tian Y, Stephens D, Widman M. The development of an injection-molding process for a polyanhydride implant containing gentamicin sulfate. PDA J Pharm Sci Technol. 2002;56:65-77.
138. Fan H, Dash AK. Effect of cross-linking on the in vitro release kinetics of doxorubicin from gelatin implants. Int J Pharm. 2001;213:103-16.
139. Itokazu M, Yamamoto K, Yang WY, Aoki T, Kato N, Watanabe K. The sustained release of antibiotic from freeze-dried fibrin-antibiotic compound and efficacies in a rat model of osteomyelitis. Infection. 1997;25:359-63.
140. Orhan Z, Cevher E, Mulazimoglu L, Gurcan D, Alper M, Araman A, Ozsoy Y. The preparation of ciprofloxacin hydrochloride-loaded chitosan and pectin microspheres: their evaluation in an animal osteomyelitis model. J Bone Joint Surg Br. 2006;88:270-5.
141. Ueng SW, Lee MS, Lin SS, Chan EC, Liu SJ. Development of a biodegradable alginate carrier system for antibiotics and bone cells. J Orthop Res. 2007;25:62-72.
142. Huneault LM, Lussier B, Dubreuil P, Chouinard L, Desevaux C. Prevention and treatment of experimental osteomyelitis in dogs with ciprofloxacin-loaded crosslinked high amylose starch implants. J Orthop Res. 2004;22:1351-7.
143. Silverman LD, Lukashova L, Herman OT, Lane JM, Boskey AL. Release of gentamicin from a tricalcium phosphate bone implant. J Orthop Res. 2007;25:23-9.
144. Dion A, Langman M, Hall G, Filiaggi M. Vancomycin release behaviour from amorphous calcium polyphosphate matrices intended for osteomyelitis treatment. Biomaterials. 2005;26:7276-85.
145. Joosten U, Joist A, Gosheger G, Liljenqvist U, Brandt B, von Eiff C. Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced chronic osteomyelitis. Biomaterials. 2005;26:5251-8.
146. Lucas-Girot A, Verdier MC, Tribut O, Sangleboeuf JC, Allain H, Oudadesse H. Gentamicin-loaded calcium carbonate materials: comparison of two drug-loading modes. J Biomed Mater Res B Appl Biomater. 2005;73B:164-70.
147. Thomas DB, Brooks DE, Bice TG, DeJong ES, Lonergan KT, Wenke JC. Tobramycin-impregnated calcium sulfate prevents infection in contaminated wounds. Clin Orthop Relat Res. 2005;441:366-71.
148. Radin S, Ducheyne P, Kamplain T, Tan BH. Silica sol-gel for the controlled release of antibiotics. I. Synthesis, characterization, and in vitro release. J Biomed Mater Res A. 2001;57:313-20.
149. Meseguer-Olmo L, Ros-Nicolas M, Vicente-Ortega V, Alcaraz-Banos M, Clavel-Sainz M, Arcos D, Ragel CV, Vallet-Regi M, Meseguer-Ortiz C. A bioactive solgel glass implant for in vivo gentamicin release. Experimental model in rabbit. J Orthop Res. 2006;24:454-60.
150. Rauschmann MA, Wichelhaus TA, Stirnal V, Dingeldein E, Zichner L, Schnettler R, Alt V. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections. Biomaterials. 2005;26:2677-84.
151. Sasaki S, Ishii Y. Apatite cement containing antibiotics: efficacy in treating experimental osteomyelitis. J Orthop Sci. 1999;4:361-9.
152. Zhang Y, Zhang M. Calcium phosphate/chitosan composite scaffolds for controlled in vitro antibiotic drug release. J Biomed Mater Res A. 2002;62:378-86.
153. Benoit MA, Mousset B, Delloye C, Bouillet R, Gillard J. Antibiotic-loaded plaster of paris implants coated with poly lactide-co-glycolide as a controlled release delivery system for the treatment of bone infections. Int Orthop. 1997;21:403-8.
154. Martins VC, Goissis G, Ribeiro AC, Marcantonio E Jr, Bet MR. The controlled release of antibiotic by hydroxyapatite: anionic collagen composites. Artif Organs. 1998;22:215-21.
155. Krisanapiboon A, Buranapanitkit B, Oungbho K. Biocompatability of hydroxyapatite composite as a local drug delivery system. J Orthop Surg (Hong Kong). 2006;14:315-8.
156. Castro C, Evora C, Baro M, Soriano I, Sanchez E. Two-month ciprofloxacin implants for multibacterial bone infections. Eur J Pharm Biopharm. 2005;60:401-6.
157. Ragel CV, Vallet-Regi M. In vitro bioactivity and gentamicin release from glasspolymer-antibiotic composites. J Biomed Mater Res A. 2000;51:424-9.
158. Fernandez M, Mendez JA, Vazquez B, San Roman J, Ginebra MP, Gil FJ, Manero JM, Planell JA. Acrylic-phosphate glasses composites as self-curing controlled delivery systems of antibiotics. J Mater Sci Mater Med. 2002;13:1251-7.
159. Makinen TJ, Veiranto M, Lankinen P, Moritz N, Jalava J, Tormala P, Aro HT. In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler. J Antimicrob Chemother. 2005;56:1063-8.
160. Murray WR. Use of antibiotic-containing bone cement. Clin Orthop Relat Res. 1984;190:89-95.
161. Calhoun JH, Mader JT. Antibiotic beads in the management of surgical infections. Am J Surg. 1989;157:443-9.
162. Miclau T, Dahners LE, Lindsey RW. In vitro pharmacokinetics of antibiotic release from locally implantable materials. J Orthop Res. 1993;11:27-32.
163. Blaha JD, Calhoun JH, Nelson CL, Henry SL, Seligson D, Esterhai JL Jr, Heppenstall RB, Mader J, Evans RP, Wilkins J, et al. Comparison of the clinical efficacy and tolerance of gentamicin PMMA beads on surgical wire versus combined and systemic therapy for osteomyelitis. Clin Orthop Relat Res. 1993;295:8-12.
164. Adams K, Couch L, Cierny G, Calhoun J, Mader JT. In vitro and in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads. Clin Orthop Relat Res. 1992;278:244-52.
165. Greene N, Holtom PD, Warren CA, Ressler RL, Shepherd L, McPherson EJ, Patzakis MJ. In vitro elution of tobramycin and vancomycin polymethylmethacrylate beads and spacers from simplex and palacos. Am J Orthop. 1998;27:201-5.
166. Montanaro L, Cavedagna D, Baldassarri L, Arciola CR. Adhesion of a Staphylococcus aureus strain to biomaterials does not select methicillin-resistant mutants. New Microbiol. 2001;24:57-61.
167. Arciola CR, Campoccia D, Montanaro L. Effects on antibiotic resistance of Staphylococcus epidermidis following adhesion to polymethylmethacrylate and to silicone surfaces. Biomaterials. 2002;23:1495-502.
168. Ambrose CG, Clanton TO. Bioabsorbable implants: review of clinical experience in orthopedic surgery. Ann Biomed Eng. 2004;32:171-7.
169. Weiss DD, Sachs MA, Woodard CR. Calcium phosphate bone cements: a comprehensive review. J Long Term Eff Med Implants. 2003;13:41-7.
170. Pioletti DP, Takei H, Lin T, Van Landuyt P, Ma QJ, Kwon SY, Sung KL. The effects of calcium phosphate cement particles on osteoblast functions. Biomaterials. 2000;21:1103-14.
171. Yu D, Wong J, Matsuda Y, Fox JL, Higuchi WI, Otsuka M. Self-setting hydroxyapatite cement: a novel skeletal drug-delivery system for antibiotics. J Pharm Sci. 1992;81:529-31.
172. Gautier H, Caillon J, Le Ray AM, Daculsi G, Merle C. Influence of isostatic compression on the stability of vancomycin loaded with a calcium phosphate-implantable drug delivery device. J Biomed Mater Res A. 2000;52:308-14.
173. Meseguer-Olmo L, Ros-Nicolas MJ, Clavel-Sainz M, Vicente-Ortega V, Alcaraz-Banos M, Lax-Perez A, Arcos D, Ragel CV, Vallet-Regi M. Biocompatibility and in vivo gentamicin release from bioactive sol-gel glass implants. J Biomed Mater Res A. 2002;61:458-65.
174. Ueng SW, Yuan LJ, Lee N, Lin SS, Liu SJ, Chan EC, Weng JH. In vivo study of hot compressing molded 50:50 poly (DL-lactide-co-glycolide) antibiotic beads in rabbits. J Orthop Res. 2002;20:654-61.
175. Wang G, Liu SJ, Ueng SW, Chan EC. The release of cefazolin and gentamicin from biodegradable PLA/PGA beads. Int J Pharm. 2004;273:203-12.
176. Liu SJ, Ueng SWN, Chan EC, Lin SS, Tsai CH, Wei FC, Shih CH. In vitro elution of vancomycin from biodegradable beads. J Biomed Mater Res B: Appl Biomater. 1999;48B:613-20.
177. Gollwitzer H, Ibrahim K, Meyer H, Mittelmeier W, Busch R, Stemberger A. Antibacterial poly(̃D,L-lactic acid) coating of medical implants using a biodegradable drug delivery technology. J Antimicrob Chemother. 2003;51:585-91.
178. Lucke M, Wildemann B, Sadoni S, Surke C, Schiller R, Stemberger A, Raschke M, Haas NP, Schmidmaier G. Systemic versus local application of gentamicin in prophylaxis of implant-related osteomyelitis in a rat model. Bone. 2005;36:770-8.
179. Radin S, El-Bassyouni G, Vresilovic EJ, Schepers E, Ducheyne P. In vivo tissue response to resorbable silica xerogels as controlled-release materials. Biomaterials. 2005;26:1043-52.
180. Saito T, Takeuchi R, Hirakawa K, Nagata N, Yoshida T, Koshino T, Okuda K, Takema M, Hori T. Slow-releasing potential of vancomycin-loaded porous hydroxyapatite blocks implanted into MRSA osteomyelitis. J Biomed Mater Res B: Appl Biomater. 2002;63B:245-51.
181. El-Ghannam A, Ahmed K, Omran M. Nanoporous delivery system to treat osteomyelitis and regenerate bone: gentamicin release kinetics and bactericidal effect. J Biomed Mater Res B: Appl Biomater. 2005;73B:277-84.
182. Murase K, Hirose H, Mori Y, Takagi H, Iwata H, Sago T, Kawamura Y. Graft-preserving treatment for vascular graft infected with Staphylococcus aureus with antibiotic-releasing porous apatite ceramic in the rabbit. J Vasc Surg. 2003;38:368-73.
183. Cevher E, Orhan Z, Mulazimoglu L, Sensoy D, Alper M, Yildiz A, Ozsoy Y. Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres. Int J Pharm. 2006;317:127-35.
184. Ueng SW, Yuan LJ, Lee N, Lin SS, Chan EC, Weng JH. In vivo study of biodegradable alginate antibiotic beads in rabbits. J Orthop Res. 2004;22:592-9.
185. Kanellakopoulou K, Kolia M, Anastassiadis A, Korakis T, Giamarellos-Bourboulis EJ, Andreopoulos A, Dounis E, Giamarellou H. Lactic acid polymers as biodegradable carriers of fluoroquinolones: an in vitro study. Antimicrob Agents Chemother. 1999;43:714-6.
186. Ramchandani M, Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J Control Release. 1998;54:167-75.
187. Pham HH, Luo P, Genin F, Dash AK. Synthesis and characterization of hydroxyapatite-ciprofloxacin delivery systems by precipitation and spray drying technique. AAPS PharmSciTech. 2002;3:E1.
188. Castro C, Sanchez E, Delgado A, Soriano I, Nunez P, Baro M, Perera A, Evora C. Ciprofloxacin implants for bone infection. In vitro-in vivo characterization. J Control Release. 2003;93:341-54.
189. Baro M, Sanchez E, Delgado A, Perera A, Evora C. In vitro-in vivo characterization of gentamicin bone implants. J Control Release. 2002;83:353-64.
190. Torrado S, Frutos P, Frutos G. Gentamicin bone cements: characterisation and release (in vitro and in vivo assays). Int J Pharm. 2001;217:57-69.
191. Changez M, Burugapalli K, Koul V, Choudhary V. The effect of composition of poly(acrylic acid)-gelatin hydrogel on gentamicin sulphate release: in vitro. Biomaterials. 2003;24:527-36.
192. Rogers-Foy JM, Powers DL, Brosnan DA, Barefoot SF, Friedman RJ, LaBerge M. Hydroxyapatite composites designed for antibiotic drug delivery and bone reconstruction: a caprine model. J Invest Surg. 1999;12:263-75.
193. Hill J, Klenerman L, Trustey S, Blowers R. Diffusion of antibiotics from acrylic bone-cement in vitro. J Bone Joint Surg Br. 1977;59:197-9.
194. Arcos D, Ragel CV, Vallet-Regi M. Bioactivity in glass/PMMA composites used as drug delivery system. Biomaterials. 2001;22:701-8.
195. Dash AK, Haney PW, Garavalia MJ. Development of an in vitro dissolution method using microdialysis sampling technique for implantable drug delivery systems. J Pharm Sci. 1999;88:1036-40.
196. Rossi S, Azghani AO, Omri A. Antimicrobial efficacy of a new antibiotic-loaded poly(hydroxybutyric-co-hydroxyvaleric acid) controlled release system. J Antimicrob Chemother. 2004;54:1013-8.
197. Frutos Cabanillas P, Diez Pena E, Barrales-Rienda JM, Frutos G. Validation and in vitro characterization of antibiotic-loaded bone cement release. Int J Pharm. 2000;209:15-26.
198. Di Silvio L, Bonfield W. Biodegradable drug delivery system for the treatment of bone infection and repair. J Mater Sci Mater Med. 1999;10:653-8.
199. Ethell MT, Bennett RA, Brown MP, Merritt K, Davidson JS, Tran T. In vitro elution of gentamicin, amikacin, and ceftiofur from polymethylmethacrylate and hydroxyapatite cement. Vet Surg. 2000;29:375-82.
200. Naraharisetti PK, Lew MD, Fu YC, Lee DJ, Wang CH. Gentamicin-loaded discs and microspheres and their modifications: characterization and in vitro release. J Control Release. 2005;102:345-59.
201. Yenice I, Calis S, Kas H, Ozalp M, Ekizoglu M, Hincal A. Biodegradable implantable teicoplanin beads for the treatment of bone infections. Int J Pharm. 2002;242:271-5.
202. Abazinge M, Jackson T, Yang Q, Owusu-Ababio G. In vitro and in vivo characterization of biodegradable enoxacin microspheres. Eur J Pharm Biopharm. 2000;49:191-4.
203. Wichelhaus TA, Dingeldein E, Rauschmann M, Kluge S, Dieterich R, Schafer V, Brade V. Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads. J Antimicrob Chemother. 2001;48:117-9.
204. Yamashita Y, Uchida A, Yamakawa T, Shinto Y, Araki N, Kato K. Treatment of chronic osteomyelitis using calcium hydroxyapatite ceramic implants impregnated with antibiotic. Int Orthop. 1998;22:247-51.
205. Bobyn JD, Wilson GJ, MacGregor DC, Pilliar RM, Weatherly GC. Effect of pore size on the peel strength of attachment of fibrous tissue to porous-surfaced implants. J Biomed Mater Res. 1982;16:571-84.
206. Klawitter JJ, Hulbert SF. Application of porous ceramics for the attachment of load bearing orthopedic applications. J Biomed Mater Res Symp. 1971;2:161-229.
207. Fogelberg EV, Zitzmann EK, Stinchfield FE. Prophylactic penicillin in orthopaedic surgery. J Bone Joint Surg Am. 1970;52:95-8.
208. Radin S, Falaize S, Lee MH, Ducheyne P. In vitro bioactivity and degradation behavior of silica xerogels intended as controlled release materials. Biomaterials. 2002;23:3113-22.
209. Li H, Chang J. Fabrication and characterization of bioactive wollastonite/PHBV composite scaffolds. Biomaterials. 2004;25:5473-80.
210. Soriano I, Evora C. Formulation of calcium phosphates/poly (d,l-lactide) blends containing gentamicin for bone implantation. J Control Release. 2000;68:121-34.
211. Gautier H, Daculsi G, Merle C. Association of vancomycin and calcium phosphate by dynamic compaction: in vitro characterization and microbiological activity. Biomaterials. 2001;22:2481-7.
212. Frazier DD, Lathi VK, Gerhart TN, Hayes WC. Ex vivo degradation of a poly(propylene glycol-fumarate) biodegradable particulate composite bone cement. J Biomed Mater Res A. 1997;35:383-9.
213. Fuentes G, Lara A, Peon E, Torres M. Preliminary evaluation of TEDMA/HEMA + HAP composites as bone substitutes and drug controlled delivery matrixes. Lat Am Appl Res. 2005;35:9-14.
214. Schnieders J, Gbureck U, Thull R, Kissel T. Controlled release of gentamicin from calcium phosphate-poly(lactic acid-co-glycolic acid) composite bone cement. Biomaterials. 2006;27:4239-49.
215. Klekamp J, Dawson JM, Haas DW, DeBoer D, Christie M. The use of vancomycin and tobramycin in acrylic bone cement: biomechanical effects and elution kinetics for use in joint arthroplasty. J Arthroplasty. 1999;14:339-46.
216. Veiranto M, Tormala P, Suokas E. In vitro mechanical and drug release properties of bioabsorbable ciprofloxacin containing and neat self-reinforced P(L/DL)LA 70/30 fixation screws. J Mater Sci Mater Med. 2002;13:1259-63.
217. Coleman NJ, Nicholson JW. Glass bones. Edu Chem. 2006;43:156-60.
218. Ogino M, Ohuchi F, Hench LL. Compositional dependence of the formation of calcium phosphate films on bioglass. J Biomed Mater Res. 1980;14:55-64.
219. Kokubo T, Kushitani H, Sakka S, Kitsugi T, Yamamuro T. Solutions able to reproduce in vivo surface-structure changes in bioactive glass-ceramic A-W. J Biomed Mater Res. 1990;24:721-34.
220. Kokubo T, Takadama H. How useful is SBF in predicting in vivo bone bioactivity? Biomaterials. 2006;27:2907-15.
221. Otsuka M, Nakahigashi Y, Matsuda Y, Fox JL, Higuchi WI, Sugiyama Y. A novel skeletal drug delivery system using self-setting calcium phosphate cement. 8: The relationship between in vitro and in vivo drug release from indomethacin-containing cement. J Control Release. 1997;43:115-22.
222. Mollo AR, Corrigan OI. Effect of poly-hydroxy aliphatic ester polymer type on amoxycillin release from cylindrical compacts. Int J Pharm. 2003;268:71-9.
223. Shi Z, Neoh KG, Kang ET, Wang W. Antibacterial and mechanical properties of bone cement impregnated with chitosan nanoparticles. Biomaterials. 2006;27:2440-9.
224. Lucke M, Schmidmaier G, Sadoni S, Wildemann B, Schiller R, Haas NP, Raschke M. Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone. 2003;32:521-31.
225. Heybeli N, Oktar FN, Ozyazgan S, Akkan G, Ozsoy S. Low-cost antibiotic loaded systems for developing countries. Technol Health Care. 2003;11:207-16.
226. Parsons RL. Antibiotics in bone. J Antimicrob Chemother. 1976;2:228-31.
227. Koort JK, Suokas E, Veiranto M, Makinen TJ, Jalava J, Tormala P, Aro HT. In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment. J Biomed Mater Res A. 2006;78:532-40.
228. Takano I, Ishii Y. Experimental study of apatite cement containing antibiotics. J Orthop Sci. 1997;2:98-105.
229. Sanchez E, Baro M, Soriano I, Perera A, Evora C. In vivo-in vitro study of biodegradable and osteointegrable gentamicin bone implants. Eur J Pharm Biopharm. 2001;52:151-8.
230. Pearce AI, Richards RG, Milz S, Schneider E, Pearce SG. Animal models for implant biomaterial research in bone: a review. Eur Cell Mater. 2007;13:1-10.
231. Gitelis S, Brebach GT. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthop Surg (Hong Kong). 2002;10:53-60.
232. Uppoor VR. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release. 2001;72:127-32.
233. Friess W, Schlapp M. Sterilization of gentamicin containing collagen/PLGA microparticle composites. Eur J Pharm Biopharm. 2006;63:176-87.
234. Price JS, Tencer AF, Arm DM, Bohach GA. Controlled release of antibiotics from coated orthopedic implants. J Biomed Mater Res A. 1996;30:281-6.
235. Nelson CL, McLaren SG, Skinner RA, Smeltzer MS, Thomas JR, Olsen KM. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. J Orthop Res. 2002;20:643-7.
236. Alvarez H, Castro C, Moujir L, Perera A, Delgado A, Soriano I, Evora C, Sanchez E. Efficacy of ciprofloxacin implants in treating experimental osteomyelitis. J Biomed Mater Res B: Appl Biomater. 2007; doi: 10.1002/jbm.b.30921.
237. Koort JK, Makinen TJ, Suokas E, Veiranto M, Jalava J, Knuuti J, Tormala P, Aro HT. Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:1502-8.
238. Deng JS, Li L, Stephens D, Tian Y, Harris FW, Cheng SZ. Effect of gamma-radiation on a polyanhydride implant containing gentamicin sulfate. Int J Pharm. 2002;232:1-10.
239. Tian Y, Li L, Gao X, Deng J, Stephens D, Robinson D, Chang H. The effect of storage temperatures on the in vitro properties of a polyanhydride implant containing gentamicin. Drug Dev Ind Pharm. 2002;28:897-903.
240. Sayin B, Calis S. Influence of accelerated storage conditions on the stability of vancomycin-loaded poly(d,l-lactide-co-glycolide) microspheres. FABAD J Pharm Sci. 2004;29:111-6.
241. Khan IA, Mirza ZM, Kumar A, Verma V, Qazi GN. Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:810-2.
242. Wu P, Grainger DW. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials. 2006;27:2450-67.
243. Suzuki Y, Tanihara M, Nishimura Y, Suzuki K, Kakimaru Y, Shimizu Y. A new drug delivery system with controlled release of antibiotic only in the presence of infection. J Biomed Mater Res A. 1998;42:112-6.
244. Woo GL, Mittelman MW, Santerre JP. Synthesis and characterization of a novel biodegradable antimicrobial polymer. Biomaterials. 2000;21:1235-46.
245. Tanihara M, Suzuki Y, Nishimura Y, Suzuki K, Kakimaru Y. Thrombin-sensitive peptide linkers for biological signal-responsive drug release systems. Peptides. 1998;19:421-5.